Sibrafiban
Sibrafiban is an investigational antiplatelet drug that was developed for the prevention of thrombotic events such as myocardial infarction and stroke. It belongs to the class of drugs known as glycoprotein IIb/IIIa inhibitors, which work by inhibiting the final common pathway for platelet aggregation.
Mechanism of Action[edit]
Sibrafiban functions by inhibiting the glycoprotein IIb/IIIa receptor on the surface of platelets. This receptor is crucial for the binding of fibrinogen and von Willebrand factor, which are essential for platelet aggregation and thrombus formation. By blocking this receptor, sibrafiban prevents the formation of blood clots.
Clinical Development[edit]
Sibrafiban was investigated in several clinical trials to assess its efficacy and safety in preventing thrombotic events in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, the development of sibrafiban was eventually discontinued due to concerns about its safety profile and the occurrence of adverse events.
Pharmacokinetics[edit]
The pharmacokinetics of sibrafiban involve its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug and its metabolites are excreted primarily through the kidneys.
Adverse Effects[edit]
Common adverse effects associated with sibrafiban include bleeding, thrombocytopenia, and gastrointestinal disturbances. Due to the increased risk of bleeding, careful monitoring is required during its use.
See Also[edit]
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
